Immersive Van Gogh will go no more. Photo by Michael Brosilow

An innovative digital production company, Lighthouse Immersive, whose "immersive" exhibits became a buzz during the height of the pandemic, has filed for Chapter 15 bankruptcy.

According to Bloomberg News, the company, which put on multiple high-profile immersive art exhibitions across the U.S. including Houston, Dallas, and San Antonio, was last profitable in 2021; but attendance dropped off after the pandemic.

Founded in Toronto in 2019, the company helped spearhead the immersive fad, first and most famously here in Houston with its 2021 Van Gogh exhibit, followed by multiple digital light shows across Houston and the U.S. including Frida Kahlo, Monet & The Impressionists, King Tut, Nutcracker, and its most recent, the immersive Disney Animation Experience.

However, in June, the company abruptly canceled the Disney show, both in Houston and Dallas — a move that appears to have been an omen of the company's financial woes. Oddly, that exhibition remains open in San Antonio through August 13.

Industry publication The Art Newspaper expressed surprise at the bankruptcy given the company's business model.

"Given the high cost of tickets ($35 a piece) and the low cost of using images that had entered the public domain, Lighthouse Immersive's operations were widely believed to be a profitable concept," says the publication.

However, these exhibits were not cheap to produce: Organizers quoted startup costs at a minimum of $1 million all the way up to $15 million to create an immersive pop-up, with expensive gear such as fiberoptic cables and Panasonic projectors.

The company has not revealed its plans nor what will happen to the venues they used in each city; they did not respond to a request for comment.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”